Two new mutations have been identified within the dihydropteridine reductase (DHPR) gene in two patients with DHPR deficiency. The total coding sequence of the cDNA has been screened by chemical cleavage of mismatch in both patients and selected portions of the cDNA have been sequenced. The first mutation identified causes a glycine to aspartic acid substitution at codon 23 and seems particularly frequent in Mediterranean patients. Its occurrence within a glycine string common to the amino-terminal region in NADH dependent enzymes suggests a possible causal mechanism for the defect. The second change involves a tryptophan to glycine substitution at codon 108 and is carried by both alleles in the second patient. It occurs in a motif which shows similarities with a region of dihydrofolate reductase (DHFR) and is highly conserved within different animal species. (J Med Genet 1993;30:465-9) 
Dihydropteridine reductase (DHPR, EC 1.6.99.7) is an essential enzyme in the hydroxylating system of the aromatic amino acids, since it catalyses the regeneration of tetrahydrobiopterin (BH4), the natural cofactor of phenylalanine, tyrosine, and tryptophan hydroxylases, from the quininoid-dihydrobiopterin produced in these coupled reactions." '3 Inherited DHPR deficiency in humans causes hyperphenylalaninaemia as well as impaired production of monoamine neurotransmitters derived from tyrosine and tryptophan, dopamine, norepinephrine, and serotonin.7 This metabolic derangement leads patients to develop progressive and irreversible brain deterioration with severe neurological symptoms including psychomotor retardation, hypotonia of the trunk with limb hypertonia, and myoclonic epilepsy. A similar phenotype is shared by two additional inborn errors of BH4 synthesis, 6-pyruvoyl tetrahydropterin synthase and GTP cyclohydrolase deficiencies, responsible for impaired cofactor availability. On the basis of worldwide series, an overall frequency of such cases of 1 to 3% has been estimated among all types of hyperphenylalaninaemia detected by newborn mass screening.8 However, higher incidences have been reported in Mediterranean and non-Caucasian populations. 9 All these disorders, at present called BH4 deficiency, are clinically unresponsive to a restricted phenylalanine diet, unlike phenylketonuria, and so they have been previously described as 'malignant' or 'atypical' hyperphenylalaninaemia. 610 The unfavourable outcome can be largely prevented by the early administration of synthetic BH4, alone or in combination with diet and substitutive neurotransmitter therapy with hydroxylated precursors."' The choice of the best treatment, and the individual adjustments required to obtain a good clinical response, are difficult to determine. Some DHPR deficient patients respond fully to BH4 administration, thus avoiding both low phenylalanine diets and neurotransmitter therapy, whereas others need neurotransmitter precursor supplementation.'2 The clinical heterogeneity of DHPR deficiency has been confirmed by enzyme studies, leading to the identification of patients carrying a mutated protein devoid of catalytic activity (DHPR-CRM+), and of others lacking any enzyme protein (DHPR-CRM-), or with different tissue distribution of residual activity.1 '15 So far, our understanding of how DHPR functions is limited. Protein chemistry has shown that the native NADH dependent enzyme exists as a homodimer with a subunit molecular weight of between 25 and 27 kDa.'6 Four cysteine residues are found in each subunit of the human and rat enzyme. [17] [18] [19] [20] The role of these cysteines is unclear; however, studies with bovine DHPR suggest that these residues do not form disulphide bridges.2' An alternate role for at least one sulphydryl group might be found in NADH binding since preincubation with NADH protects the enzyme against inhibition by a wide range of thiol modifying agents. 16 17 22 Further information and possible genotypephenotype correlations may arise from the identification of the underlying causal genetic lesions in patients with different clinical presentations.
The cDNA sequence (and by inference the amino acid sequence) of both human and rat DHPR have been determined1820 and the rat DHPR has been shown to have a region of similarity with other NADH dependent enzymes. 23 So far it seems that most cases of DHPR deficiency result from point mutations, since analysis of the restriction map excludes any large deletion occurring within the gene. Molecular heterogeneity is, however, expected for this disease, as inferred from the clinical presentation and Northern analysis.'8 Recently, the first causal mutation has been identified in a Turkish patient, the insertion of the triplet ACT (threonine) after alanine 122. 24 We 3A) . Sequencing of this region showed a G to A conversion at base 420 changing CTG to CTA, conserving the Leu 132 codon ( fig 3C) . No other CCM reactivity was seen for case 1 with either hydroxylamine or osmium tetroxide in IF or AD PCR products. However, sequencing of the I-F PCR product of case 1 showed a T to G conversion at base 346 that changed the codon for tryptophan 108 (TGG) to a glycine codon (GGG) (fig 3B) . This T to G alteration (which forms a T/C mismatch with the T in the labelled strand) was not detected by the CCM method, probably because of the high stability of the surrounding G/C base pairs (Cotton et al, submitted). This problem can be overcome by using a slightly different CCM proced- ure.32 33 Since all the five sequenced M13 clones carried this change at codon 108 and since case 1 was born to consanguineous parents, he is homozygous for this mutation.
Discussion
In this paper we report two new mutations affecting the DHPR gene in two patients with DHPR deficiency. The mutation in case 2 is a conversion of glycine to aspartate at codon 23. This glycine is located within a highly conserved 'glycine fingerprint' found in human DHPR (fig 4) and common to most NADH binding enzymes at their amino-terminal.3435 In these enzymes a I-a-f fold is centred around a highly conserved sequence Gly-X-Gly-X-X-Gly (where X is any amino acid) that constitutes a tight turn at the end of the first strand of a f sheet and marks the beginning of the subsequent a helix. The first glycine residue is essential for the tightness of the turn, the second allows the dinucleotide to be bound without obstruction from an amino acid side chain at this position, and the third provides space to allow close association between the ,B strands and the a helix. 35 Glycine at codon 23 in DHPR corresponds to the third of these glycines. Thus it may be expected that the insertion of the bulkier and negatively charged aspartic acid disrupts the geometry of a possible NADH binding site and suggests a mechanism for DHPR deficiency in case 2. It is interesting in 5) . Mutation of one of these conserved residues, Trp 108 to glycine, was identified in case 1 and, interestingly, the threonine insertion immediately after Ala 122, the first mutation recognised in a DHPR deficient gene, also lies in this region24 (fig 5) .
In DHFR substitution of phenylalanine for Trp 24, corresponding to Trp 108 in DHPR, results in a more flexible conformation that shows general reduction in affinity for its substrates,37 suggesting that this residue plays a role in maintaining the structural integrity of DHFR. On the other hand, in rat DHPR substitution of phenylalanine for Trp 104 (the residue equivalent to human DHPR, Trp 108) increased the Km for NADH but did not significantly reduce Kcat. However, it is important to observe that in both these cases the mutation is conservative, since both phenylalanine and tryptophan are aromatic amino acids. Expression studies fit well with the former suggestion, since the DHPR protein with Trp 108 to Gly substitution shows an increased in vitro susceptibility to digestion by proteolytic enzymes (Smooker et al, submitted). Thus, this mutation probably inactivates DHPR by causing aberrant folding of the protein and consequent disruption of a region of functional importance. The hypothesis of an encoded non-functional protein is in agreement with the finding of CRM + material within fibroblasts from this patient, homozygous for the Trp to Gly substitution.
Finally, our study identified the change of the CTG codon for Leu 132 to CTA, an alternate leucine codon, in case 1 and in control SI 16 ( fig 2) . This change has been reported previously in another child with DHPR deficiency indicating that this is a common polymorphism.24 However, even harmless polymorphisms may be of clinical value in populations (or for diseases) where most of the causal mutations are unknown, since they allow the mutant allele to be traced in family studies.
In conclusion, two new mutations have been characterised in two patients with DHPR deficiency. The localisation of the mutations within highly conserved amino acid motifs within the protein and the preliminary results of expression studies suggest that they are most probably causal. Identification of the Gly 23 to Asp substitution in several patients of Mediterranean origin suggests that this mutation may be the most frequent molecular Figure 5 Comparison of the sequences of DHPR and DHFR in a highly conserved portion of DHFR. Boxes indicate the conserved residues, asterisks indicate residues absolutely conserved in several species of DHFR. ' 
